Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trialValentina Guarneri, PierFranco Conte, Maria Vittoria Dieci et al.|European Journal of Cancer|2021Cited by 42
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in ItalyFrancesco Cognetti, Sandro Barni, Giovanna Catania et al.|npj Breast Cancer|2021Cited by 29
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer (BC).Valentina Guarneri, PierFranco Conte, Maria Vittoria Dieci et al.|Journal of Clinical Oncology|2020Cited by 3